VJDementia is committed to improving our service to you

Share this video  

VJDementia is committed to improving our service to you

AD/PD 2022 | Single center pilot study of TPS in Alzheimer’s disease

Lars Wojtecki, MD, PhD, University of Düsseldorf, Düsseldorf, Germany, discusses the use of transcranial pulse stimulation (TPS), a new therapy that uses shockwaves, for the treatment of Alzheimer´s disease. An Austrian clinical trial provided the first evidence for beneficial clinical effects in patients with Alzheimer’s disease. However, the trial is still running, and placebo-controlled results are not yet available. Prof. Wojtecki reports on the first German pilot study of TPS in Alzheimer’s disease patients. The results showed that all patients improved at least transiently in one test (e.g., ADAS, MMST, MoCa, BDI). Further studies are needed, in particular, biomarkers studies to track treatment changes and improve patient selection. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed. Vertanical
Stock Ownership: BionTech